# EDGAR Filing Document

**Accession Number:** 0001859807
**File Stem:** 0001213900-25-124826
**Filing Date:** 2025-12
**Character Count:** 29607
**Document Hash:** 15506a5db135c9a7fd77878a778b7e00
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-124826.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001213900-25-124826

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 19

**CONFORMED PERIOD OF REPORT**: 20251222

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Profusa, Inc.
- **CENTRAL INDEX KEY:** 0001859807
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 863437271
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41177
- **FILM NUMBER:** 251594593

**BUSINESS ADDRESS:**
- **STREET 1:** 207 WEST 25TH ST, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001
- **BUSINESS PHONE:** 212-494-9022

**MAIL ADDRESS:**
- **STREET 1:** 207 WEST 25TH ST, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NorthView Acquisition Corp
- **DATE OF NAME CHANGE:** 20210429

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): December 22, 2025

**PROFUSA, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41177** | **86-3437271** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

**626 Bancroft Way, Suite A**

**Berkeley, CA 94710**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (**925) 997-6925**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | PFSA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

*Amendment No. 1 to Securities Purchase Agreement dated July 28, 2025*

 

As previously disclosed in the prospectus on Form 424B3 filed on October 29, 2025 by Profusa, Inc. (the "**Company**") with the Securities and Exchange Commission (the "**SEC**"), the Company entered into a Securities Purchase Agreement, dated July 28, 2025 (the "**Purchase Agreement**") with Ascent Partners Fund LLC ("**Ascent**") pursuant to which, the Company may, from time to time and at its discretion, issue and sell to Ascent shares of its common stock (the "**Purchased Securities**") for an aggregate purchase price of up to $100,000,000 (the "**Maximum Aggregate Purchase Price**"), subject to certain limitations and conditions.

On December 22, 2025, the Company entered into Amendment No. 1 (the "**SPA Amendment**") to the Purchase Agreement. Pursuant to the SPA Amendment, Section 1.1 of the Purchase Agreement was amended and restated to modify the definition of Floor Price to provide for a Floor Price at or above 11.1 cents ($0.111) per share during the period commencing on the date of the SPA Amendment and ending on, but excluding, the effective date of the reverse stock split expected to be presented to the Company's stockholders in January 2026 for their approval, if and when such reverse stock split becomes effective (the "Modification Period"). The "Floor Price" as amended and restated means, during the Modification Period, solely with respect to an aggregate number of shares of Common Stock issued and sold as Purchased Securities not to exceed 13,650,000 shares, to be sold at or above 11.1 cents ($0.111) per share and below 14 cents ($0.14). Upon the earliest to occur of (x) the issuance of such aggregate number of 13,650,000 shares as Purchased Securities during the Modification Period or (y) the end of the Modification Period, the Floor Price shall thereafter mean 14 cents ($0.14), the price per share of Common Stock equal to the product obtained by multiplying (x) twenty percent (20%) by (y) the Official Closing Price on July 25, 2025, in each case as further adjusted to reflect any reduction (but excluding any increase) in the price per share of Common Stock caused by any reorganization, recapitalization, non-cash dividend, share split or other similar transaction, all as provided in this Agreement. The modified Floor Price of 11.1 cents ($0.111) per share applies only during the Modification Period and only up to the 13,650,000 share cap relating to shares issued and sold below 14 cents ($0.14), and the unmodified definition applies to all other times and shares.

The foregoing description of Amendment No. 1 to the Securities Purchase Agreement is a summary only and does not purport to be complete and is qualified in its entirety by reference to the full text of the SPA Amendment, a copy of which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

*Amendment No. 2 to Amended Senior Secured Convertible Promissory Note*

 

As previously disclosed in the Current Report on Form 8-K filed by the Company with the SEC on February 18, 2025, in connection with the closing of the First Tranche, the Company entered into a Senior Secured Convertible Promissory Note, dated February 11, 2025 (the "**Note**") with Ascent pursuant to a Securities Purchase Agreement, dated February 11, 2025, by and between the Company and Ascent. As previously disclosed in the Current Report on Form 8-K filed by the Company with the SEC on August 26, 2025, the Company entered into Amendment No. 1 (the "**Note Amendment**") to the Note, which modified the terms of the Note, specifically amending Section 4(b) to revise the conversion price provisions on any conversion date to be the lower of (i) the Conversion Price on such date and (ii) ninety-five percent (95%) of the lowest daily volume weighted average price ("**VWAP**") for the Company's common stock during the ten consecutive trading days immediately preceding the applicable conversion date (the "**Alternate Conversion Price**"), provided that in no event shall the conversion price be less than the Floor Price of twenty percent (20%) of the closing sale price of the common stock on the principal trading market on the trading day immediately preceding the Amendment's effective date.

On December 22, 2025, the Company entered into Amendment No. 2 (the "**Second Note Amendment**") to the Note. The Second Note Amendment modifies the terms of the Note, specifically amending (i) Section 2(a) of the Note to eliminate the amortization provisions and related payments, a change that the parties intended to include in Amendment No.1 and that was inadvertently omitted from Amendment No.1, (as well as conforming changes to other sections of the Note); and (ii) Section 2(b) to revise the Mandatory Prepayment Amount for any Subsequent Offering that is an Equity Line of Credit to thirty-three and three tenths percent (33.3%) of the net proceeds of such Equity Line of Credit.

The foregoing description of Amendment No. 2 to the Senior Secured Convertible Promissory Note is a summary only and does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Note Amendment, a copy of which is filed herewith as Exhibit 10.2 and is incorporated herein by reference. Defined terms used in the foregoing summary, but not otherwise defined, have the respective meanings ascribed to them in the Note, the form of which is filed as Exhibit 10.3 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

Exhibits.

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 10.1 | [Amendment No. 1, dated December 22, 2025, to the Securities Purchase Agreement dated July 28, 2025, by and between Profusa, Inc. and Ascent Partners Fund LLC.](ea027077201ex10-1_profusa.htm) |
| 10.2 | [Amendment No. 2, dated December 22, 2025, to the Senior Secured Convertible Promissory Note issued by Profusa, Inc. on February 11, 2025, for the benefit of Ascent Partners Fund LLC.](ea027077201ex10-2_profusa.htm) |
| 10.3 | [Form of Amended Senior Secured Convertible Promissory Note (incorporated by reference to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 26, 2025).](http://www.sec.gov/Archives/edgar/data/1859807/000121390025080457/ea025456401ex10-3_profusa.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| December 23, 2025 | **Profusa, Inc.** | **Profusa, Inc.** |
|  | By: | */s/ Ben Hwang* |
|  | Name: | Ben Hwang |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

***Execution Version***

**19505 Biscayne Blvd. ● Suite 2350 ● Aventura, FL 33180 ● legal@ascentpartnersllc.com**

To: Profusa, Inc.

626 Bancroft Way, Suite A

Berkeley, CA

Attention: Fred Knechtel, CFO

**Amendment No. 1 to Securities Purchase Agreement**

December 22, 2025

Re: Amendment No. 1

Dear Fred:

Reference is made to that certain Securities Purchase Agreement, dated as of July 28, 2025 (as modified to the date hereof, the "Purchase Agreement"), by and between Profusa, Inc. (together with its successors and permitted assigns, the "Company") and Ascent Partners Fund LLC, a Delaware limited liability company (together with its successors and permitted assigns, the "Purchaser"). Capitalized terms used but not defined herein have the meanings ascribed to them in the Purchase Agreement.

Subject to the terms and conditions set forth herein, and effective on (i) the date hereof and (ii) the date of payment of all Obligations due on or before, but after giving effect to, the effective date of this amendment (including payment of the Amendment Fee and all other costs, expenses and fees due under any Transaction Document after giving effect to this amendment and invoiced prior to such effective date) (the **"Amendment Effective Date")**, the following Transaction Documents are hereby amended as follows:

 ****

***Purchase Agreement***

Section 1.1 (Definitions)—Addition of "Modification Period". Section 1.1 of the Purchase Agreement is amended to add the following definition in alphabetical order:

"Modification Period" means the period commencing on and including the Amendment Effective Date and ending on, but excluding, the effective date of the reverse stock split expected to be presented to the Company's stockholders in January 2026 for their approval, if and when such reverse stock split becomes effective.

![](ex10-1_002.jpg)

Section 1.1 (Definitions)—Amendment and Restatement of "Floor Price". The definition of "Floor Price" in Section 1.1 of the Purchase Agreement is hereby amended and restated in its entirety to read as follows:

"Floor Price" means, during the Modification Period, solely with respect to an aggregate number of shares of Common Stock issued and sold as Purchased Securities not to exceed 13,650,000 shares, to be sold at or above 11.1 cents ($0.111) per share and below 14 cents ($0.14). Upon the earliest to occur of (x) the issuance of such aggregate number of 13,650,000 shares as Purchased Securities during the Modification Period or (y) the end of the Modification Period, the Floor Price shall thereafter mean 14 cents ($0.14), the price per share of Common Stock equal to the product obtained by multiplying (x) twenty percent (20%) by (y) the Official Closing Price on July 25, 2025, in each case as further adjusted to reflect any reduction (but excluding any increase) in the price per share of Common Stock caused by any reorganization, recapitalization, non-cash dividend, share split or other similar transaction, all as provided in this Agreement. For the avoidance of doubt, the modified Floor Price of 11.1 cents ($0.111) per share applies only during the Modification Period and only up to the foregoing aggregate share cap relating to shares issued and sold below14 cents ($0.14), and the unmodified definition applies to all other times and shares.

Conforming Provisions. References in the Purchase Agreement and the other Transaction Documents to "Floor Price" shall be deemed to refer to "Floor Price" as amended hereby, including for purposes of Section 2.1(b) and the Purchaser's option to reject any Advance Notice where the Closing Price is less than the Floor Price, and for purposes of the Valuation Period calculation excluding Trading Days on which the Common Stock is less than the Floor Price.

Reaffirmations; Miscellaneous

A. No Other Changes. Except as expressly amended hereby, all terms and provisions of the Purchase Agreement and the other Transaction Documents remain in full force and effect and are hereby ratified and confirmed in all respects. From and after the Amendment Effective Date, all references in any Transaction Document to the "Purchase Agreement," "hereof," "hereunder," and words of similar import shall be deemed to refer to the Purchase Agreement as amended hereby.

B. No Waiver. The execution, delivery and effectiveness of this amendment shall not operate as a waiver of any right, power or remedy of the Purchaser under the Purchase Agreement or any other Transaction Document, nor constitute a waiver of any Default or Event of Default, if any, whether known or unknown, now existing or hereafter arising.

C. Fees and Expenses; Transaction Document. This amendment constitutes a "Transaction Document" and is subject to the provisions of the Purchase Agreement applicable to Transaction Documents, including provisions regarding fees and expenses, counterparts, electronic signatures, notices, governing law, submission to jurisdiction, waiver of jury trial, interpretation, and severability.

D. Governing Law; Venue. This amendment shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware. Any Proceeding with respect hereto shall be brought exclusively in the state or federal courts sitting in Wilmington, Delaware, subject to the exceptions set forth in the Purchase Agreement.

*[Signature Pages Follow]*

![](ex10-1_002.jpg)

This amendment may be executed in counterparts, which may be effectively transmitted by fax or e-mail (in each case return receipt requested and obtained) and which, together, shall constitute one and the same instrument.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| ASCENT PARTNERS FUND LLC, | ASCENT PARTNERS FUND LLC, |
| as Holder | as Holder |
| By: |  |
|  | Name: |
|  | Title: |

---

Accepted and Agreed<br> As of the Date First Written Above:

---

| | |
|:---|:---|
| Profusa, Inc. | Profusa, Inc. |
| By: |  |
| Name: | Fred Knechtel |
| Title: | Chief Financial Officer |

---

![](ex10-1_002.jpg)

## Exhibit 10.2

**Exhibit 10.2**

***Execution Version***

![](ex10-2_001.jpg)

**19505 Biscayne Blvd. ● Suite 2350 ● Aventura, FL 33180 ● legal@ascentpartnersllc.com**

To: Profusa, Inc.

626 Bancroft Way, Suite A

Berkeley, CA

Attention: Fred Knechtel, CFO

**Amendment No. 2 to Amended Senior Secured Convertible Promissory Note**

December 22, 2025

Re: Amendment No. 1

Dear Fred:

Reference is made to that certain Senior Secured Convertible Promissory Note, dated as of February 11, 2025 (as previously amended, restated, supplemented or otherwise modified, including pursuant to that certain Amendment No. 1 dated August 25, 2025, the "Note"), issued by Profusa, Inc., a Delaware corporation (together with its successors and permitted assigns, the "Company"), for the benefit of Ascent Partners Fund LLC, a Delaware limited liability company (together with its successors and registered assigns, the "Holder"), is entered into as of December 22, 2025, by and among the Company, the Holder, and, solely for purposes of the reaffirmations herein, the other Company Parties party to the Note and related Transaction Documents. Capitalized terms used but not defined herein have the meanings set forth in the Note or, if not defined therein, in the Securities Purchase Agreement, dated as of February 11, 2025, by and among the Company and the Holder (as amended, the "Purchase Agreement"). By way of clarification, the modification of Section 2(a) of the Note addressed in Section 2 below reflects that understanding of the parties concluded at the time of the execution of Amendment No. 1 that failed to be reflected in Amendment No. 1.

Subject to the terms and conditions set forth herein, and effective on (i) the date hereof and (ii) the date of payment of all Obligations due on or before, but after giving effect to, the effective date of this amendment (including payment of the Amendment Fee and all other costs, expenses and fees due under any Transaction Document after giving effect to this amendment and invoiced prior to such effective date) (the "Amendment Effective Date"), the following Transaction Documents are hereby amended as follows:

***Purchase Agreement***

● None

 **

 ****

 

***Note***

● Section 2(b)-Amendment to Mandatory Prepayments (Equity Line of Credit). Section 2(b) of the Note (Mandatory Prepayments) is hereby amended by deleting the reference to "17.5%" in the clause addressing Subsequent Offerings that are an Equity Line of Credit and replacing it with "33.3%," such that, for any Subsequent Offering that is an Equity Line of Credit, the Mandatory Prepayment Amount shall equal thirty-three and three tenths percent (33.3%) of the net proceeds of such Equity Line of Credit. For clarity, the 25% prepayment for Subsequent Offerings other than an Equity Line of Credit remains unchanged.

● Section 2(a)-Amortization of Principal. Elimination of Amortization Schedule and Related Payments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Section 2(a) of the Note (Amortization of Principal) is hereby deleted in its entirety and replaced with "Reserved." The Company shall have no obligation to make any monthly Amortization Payments, and the payment schedule set forth on Schedule 2 to the Note is deleted in its entirety. All references in the Note and any other Transaction Document to "Amortization Payment," "Amortization Payment Date," and "Schedule 2" are hereby deleted and of no further force or effect. For the avoidance of doubt, all Obligations (including the remaining principal and accrued and unpaid interest) shall remain due and payable on the Maturity Date or as otherwise provided in the Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Conforming Change to Section 2(d). In Section 2(d) of the Note (Interest), the sentence that begins with "provided, that, if such principal repayment is a regularly scheduled Amortization Payment set forth on Schedule 2" is hereby deleted in its entirety, and all cross-references therein to Amortization Payments are of no further force or effect. For clarity, interest (including any Minimum Interest Amount) will continue to be paid in Common Stock at the Amortization Price to the extent and on the conditions set forth in the Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Defined Terms. The defined terms "Amortization Payment" and "Amortization Payment Date" are deleted from Section 1 of the Note and any other Transaction Document. For clarity, the defined term "Amortization Price" shall remain in effect for all purposes for which it is used in the Note, including, without limitation, interest or other payments permitted to be made in Common Stock.

● No Other Changes. Except as expressly amended pursuant to Sections 1 and 2 above, the Note, as previously amended by Amendment No. 1 dated August 25, 2025 (including the Floor Price and the Conversion Price mechanics set forth therein), remains unmodified, in full force and effect, and is hereby ratified and confirmed in all respects. Without limitation, all provisions regarding the Floor Price and the Alternate Conversion Price as set forth in Amendment No. 1 remain unchanged.

![](ex10-2_002.jpg)

● Reaffirmation; Liens Unimpaired. Each Company Party reaffirms (a) all of its obligations and liabilities under the Transaction Documents (as amended hereby) and agrees that such obligations and liabilities shall remain in full force and effect and (b) all Liens granted under the Transaction Documents, which shall continue to secure the Obligations.

This amendment is a Transaction Document and is limited as written. As of the date first written above, each reference in the Purchase Agreement or the Note to "**this Agreement**," **"this Note,"** "**hereunder**," "**hereof**," "**herein**," or words of like import, and each reference in the other Transaction Documents to the Purchase Agreement or the Note (including, without limitation, by means of words like "**thereunder**," "**thereof**" and words of like import), shall refer to the Purchase Agreement or, as the case may be, the Note as modified thereby, and the provisions in this amendment amending the Purchase Agreement and the Note shall be read together and construed as a single agreement with the Purchase Agreement or, as the case may be, the Note. The execution, delivery and effectiveness of this amendment shall not, except as expressly provided herein, (A) waive or modify any Default or Event of Default (whether or not existing on the date hereof), right, power or remedy under, or any other provision of, any Transaction Document (in each case, other than any failure to comply with any provision of a Transaction Document amended hereby that would not have been a failure if such Transaction Document had been amended as provided herein prior to the date hereof) or (B) commit or otherwise obligate the Holder or the Collateral Agent to enter into or consider entering into any other consent, waiver or modification of any Transaction Document or make any further purchases or other advances pursuant to any Transaction Documents. This amendment does not constitute a novation of the Note.

Each Company Party hereby agrees that it continues to guaranty, jointly and severally, absolutely, unconditionally and irrevocably, pursuant to the Guaranty, as primary obligor and not merely as surety, the full and punctual payment when due of the Obligations of any other Company Party owing under the Transaction Document as modified hereby (subject to the limitations set forth in the Guaranty) and that the terms hereof shall not affect in any way its obligations and liabilities, as expressly modified hereby, under the Transaction Documents. Each Company Party hereby reaffirms (a) all of its obligations and liabilities under the Transaction Documents as modified hereby, and agrees that such obligations and liabilities shall remain in full force and effect and (b) all Liens granted under the Transaction Documents, and agrees that such Liens shall continue to secure the Obligations.

![](ex10-2_002.jpg)

In further consideration for the execution of this amendment by the Holder and without limiting any rights or remedies the Holder or any of its Related Parties may have, each Company Party hereby releases each of the Holder and each of its Related Parties (each a "**Releasee**" and, collectively, the "**Releasees**") against any and all claims and from any other Losses of any Company Party or any Subsidiary thereof, whether or not relating to any Transaction Document, any obligation or liability owing thereunder, any asset of any Company Party or any of their Subsidiaries or Affiliates, or any legal relationship that exists or may exist between any Releasee and any Company Party or any Subsidiary of any Company Party. Each Company Party, each for itself and for its Subsidiaries, acknowledges and agrees that it or its Subsidiaries may discover information later that could have affected materially their willingness to agree to the release in this paragraph and that neither such possibility, which it took into account when executing this amendment, nor such discovery, as to which it expressly assumes the risk, shall affect the effectiveness of the release in this paragraph, and waives the benefit of any legal requirement that may provide otherwise.

As a Transaction Document, this amendment is subject to various interpretative and miscellaneous sections set forth in the Purchase Agreement and other Transaction Documents that apply expressly to all Transaction Documents, located principally **Article VI (Miscellaneous)** of the Purchase Agreement (but also, without limitation, in **Section 4.14 (Indemnification)** thereof), including **Section 6.2 (Fees and Expenses)** thereof (which provides, without limitation, reimbursement to the Purchaser Parties for fees, costs and expenses of negotiation, preparation, execution and signing of this amendment or otherwise relating to this amendment or the transactions contemplated herein) and **Sections 6.3(a) (Entire Agreement), 6.3(b) (Amendments), 6.3(c) (Beneficiary, Successors and Assigns), 6.3(d) (No Implied Waivers or Notice Rights), 6.3(e) (Counterparts), Section 6.3(f) (Electronic Signatures)**, **6.4 (Notices), 6.7 (Severability) and 6.15 (Interpretation)** (containing various interpretative provisions and additional definitions) thereof. In addition, without limitation, (a) **Section 6.6 (Governing Law and Courts)** thereof provides that this amendment shall be governed by and construed in accordance with the laws of the State of Delaware and that Proceedings in respect hereto shall be brought exclusively in the Delaware state courts sitting in Wilmington, DE or the federal courts for the District of Delaware sitting in Wilmington, DE (subject to certain exceptions for enforcement Proceedings brought by the Collateral Agent or any Purchaser Party) and (b) in **Section 6.16 (Waiver of Jury Trial, Certain Other Rights)**, **the parties thereto (which include the parties hereto) thereby irrevocably and unconditionally waived, to the fullest extent permitted by applicable Regulations, any right that they may have to trial by jury of any claim or cause of action or in any Proceeding, directly or indirectly based upon or arising out of, under or in connection with, this amendment or the transactions contemplated therein or related thereto (whether founded in contract, tort or any other theory).** The parties hereto hereby reaffirm all of these and all other provisions of the Transaction Documents applying to the Transaction Documents as applying to this amendment, all of which are hereby incorporated herein by reference. If the Amendment Effective Date has not occurred within two Business Days after the date hereof, the Collateral Agent may, in its sole discretion upon notice to the Company, elect to terminate this amendment, at which point this amendment (including the provisions requiring payment of the Amendment Fee) will be of no further force and effect.

*[Signature Page Follows]*

![](ex10-2_002.jpg)

This amendment may be executed in counterparts, which may be effectively transmitted by fax or e-mail (in each case return receipt requested and obtained) and which, together, shall constitute one and the same instrument.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| ASCENT PARTNERS FUND LLC, | ASCENT PARTNERS FUND LLC, |
| as Holder | as Holder |
| By: |  |
|  | Name: |
|  | Title: |

---

Accepted and Agreed<br> As of the Date First Written Above:

---

| |
|:---|
| Profusa, Inc., a Delaware corporation |
| By: |
| Name: |
| Title: |
| Profusa, Inc., a California corporation (as Company Party) |
| By: |
| Name: |
| Title: |
| Ben Hwang (as Company Party) |
| By: |
| Bill McMillian (as Company Party) |
| By: |
| Northview Sponsor I LLC (as Company Party) |
| By: |
| Name: |
| Title: |

---

![](ex10-2_002.jpg)